Editas Medicine Announces First Quarter 2022 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Editas Medicine (EDIT) PT Lowered to $15 at Stifel
May 4, 2022 3:53 PM EDTStifel analyst Dae Gon Ha lowered the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $19.00) while maintaining a Hold rating.
The analyst commented, "No changes to our thesis pending clarity on the therapeutic profile of EDIT-101 (Leber congenital amaurosis type 10 [LCA10])... More
Editas Medicine (EDIT) Tops Q1 EPS by 5c
May 4, 2022 6:51 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.74), $0.05 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $3.85 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More